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Purpose: The aim of this study was to analyze and compare foot health and general health 
in a sample of women divided into two groups: 1) those with breast cancer and undergoing 
chemotherapy treatment and 2) healthy women without breast cancer and with normalized 
reference values.
Methods: A case–control observational study was performed. Two-hundred women with a 
mean age of 51.00±8.75 years were recruited from podiatric medicine and surgery clinics from 
the University of Extremadura (Plasencia, Spain) and the Hospital Infanta Cristina (Badajoz, 
Spain). The women were divided into case and control groups (undergoing chemotherapy 
treatment and healthy women, respectively). The Foot Health Status Questionnaire was used to 
assess foot health domain scores.
Results: Significant differences between both groups were seen for foot pain (P=0.003), foot 
function (P<0.001), physical activity (P<0.001), social capacity (P<0.001), and vigor (P=0.001). 
The remaining domains (footwear, general health, and foot health) did not show significant 
differences between the two groups (P≥0.01).
Conclusion: Women with breast cancer presented a lower foot health-related quality of life. 
Clinical aspects with emphasis on foot pain and disability were increased. Furthermore, physical 
activity, social capacity, and vigor were affected. Therefore, general health care and foot problem 
prevention for breast cancer survivors should be given more consideration.
Keywords: breast cancer, chemotherapy, foot injury, quality of life
Introduction
Quality of life (QoL) is an important health indicator in cancer patients. Cancer is 
viewed as the main cause of death worldwide, and it also has a significant social impact 
on patients.1 Among QoL studies in cancer patients, breast cancer has received the 
most attention.2 This disease affects the QoL of these women.3 QoL measurements 
during cancer patients’ treatment has become an important tool over the last several 
years as it provides information about physical, emotional, and/or social aspects in 
addition to disease-associated symptoms and their treatments.4 Cancer treatments 
such as chemotherapy may produce side effects and symptoms that negatively affect 
a patient’s QoL, and treatments such as mastectomies can cause lower self-esteem.5 
Other aspects such as psychosocial and medical factors (age, education, emotional, 
labor, and/or economic situations) can influence a patient’s QoL.4 Based on these 
aspects, foot care and its follow-up should be considered for patients suffering from 
common foot problems.3
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Breast cancer is the major cancer that is prevalent among 
women, especially in those aged >50 years.6,7 The World 
Health Organization has stated that breast cancer is the lead-
ing cause of cancer death worldwide, with varying incidences 
across countries. When considering developed countries, it 
has been shown that cancer-related mortality rates are declin-
ing.6,8–10 In 2012, a new global study detected approximately 
1.67 million newly diagnosed breast cancer cases in women.3
Breast cancer-associated chemotherapy also leads to side 
effects, and certain chemotherapy regimens can cause, with 
regard to the limbs, hand–foot syndrome or palmoplantar 
erythrodysesthesia, which has already been described in the 
scientific literature. Hand–foot syndrome is a skin reaction 
that occurs when a small amount of medicine gets filtered 
out of the capillaries (small blood vessels) and into the skin, 
especially into the skin of the palms of the hands and soles 
of the feet. After the drug has filtered out of the capillaries 
into the skin, it can damage the surrounding tissues. The 
hand–foot syndrome can be painful and may affect a patient’s 
daily life; therefore, this study evaluated the symptoms that 
appeared in the feet of women with breast cancer who were 
undergoing chemotherapy. Thus, this could permit develop-
ment of strategies to prevent these symptoms and improve 
the QoL of these women. Several signs and symptoms of 
the hand–foot syndrome have been reported in the scientific 
literature: 1) numbness; 2) tingling; 3) burning or itching; 4) 
redness (similar to sunburn); 5) inflammation; 6) discomfort; 
7) tenderness; and 8) rash.11,12
Foot conditions and deformities should be taken into 
consideration in these patients in an attempt to provide better 
QoL in addition to looking after the general and podiatric 
well-being of these women. Therefore, the main purpose of 
this study was to analyze and compare both foot health and 
general health in two groups of women: 1) those with breast 
cancer undergoing chemotherapy treatment and 2) those 
without breast cancer (healthy women with normal refer-
ences values). The second aim of this study was to observe 
the most frequent podiatric pathologies that may appear in 
the population of women with breast cancer and influence 
foot and general health-related QoL.
Materials and methods
Design and sample
This design was a descriptive, observational, case–control 
study that was performed following the Strengthening the 
Reporting of Observational Studies in Epidemiology state-
ment and checklist.13 Between January 2016 and May 2017, 
200 patients were recruited from podiatric medicine and 
surgery clinics that provided treatment for foot diseases and 
disorders at University of Extremadura (Plasencia, Spain) and 
the Hospital Infanta Cristina (Badajoz, Spain). A consecutive 
sampling method was used to select the 200 participants. All 
patients provided consent and were enrolled in the study.
Inclusion criteria for the case group were women 
>18 years of age with breast cancer diagnosed by an oncolo-
gist and those who were undergoing chemotherapy treatment. 
Regarding the case group, patients with breast cancer had 
been undergoing chemotherapy treatment and were recruited 
during the time from the first session to the first year of 
treatment with chemotherapy. The control group consisted 
of healthy women without cancer.
Exclusion criteria for both groups were women <18 years 
of age, presence of other types of cancer, previous radiother-
apy treatments, existence of foot deformities prior to under-
going chemotherapy treatment, neurological alterations, any 
systemic or chronic diseases, being non- or semi-independent 
in daily activities, and/or unable to understand instructions.
Sample size calculation
Sample size calculation was performed by means of the dif-
ference between two independent groups using the G*Power 
3.1.9.2 software and based on the foot function domain scores 
(mean ± standard deviation [SD]) from the Foot Health Status 
Questionnaire (FHSQ) from a pilot study (n=40) with the 
two groups.14,15 A case group consisting of 20 women with 
breast cancer undergoing chemotherapy treatment (FHSQ 
foot function domain score =67.95±27.53) and a control 
group consisting of 20 healthy women (FHSQ foot function 
domain score =54.37±29.80) were used for the data analysis. 
Indeed, a one-tailed hypothesis, an effect size of 0.47, an α 
error probability of 0.01, a power (1-β error probability) of 
0.80, and an allocation ratio (N2/N1) of 1 were used for the 
sample size calculations. Therefore, a total sample size of 
182 women, 91 in each group, was estimated.
Procedure
A single trained examiner, who measured height and weight, 
examined each participant. Furthermore, body mass index 
(BMI) was calculated with height (meters) and weight (kilo-
grams) using Quetelet’s equation (BMI = weight/height²).16 
All subjects were asked to complete the FHSQ.15 The 
investigator remained throughout the process of completing 
the questionnaire to help resolve any misunderstandings. 
Furthermore, the podiatric examiner performed a thorough 
examination in order to observe the foot pathologies that 
appeared after chemotherapy treatment.
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Section 1 of the questionnaire consists of 13 questions 
reflecting foot health-related domains such as foot pain, foot 
function, footwear, and general foot health. This question-
naire has demonstrated a high degree of content, criterion, 
construct validity (Cronbach α =0.89–0.95), and high retest 
reliability (intraclass correlation coefficient =0.74–0.92).15 
Indeed, this assessment tool was shown to be the most appro-
priate measure of foot health-related QoL. This questionnaire 
presents 13 questions that assess four health domains of the 
feet: 1) pain; 2) function; 3) general health; and 4) footwear. 
Each domain has a specific number of questions (four ques-
tions with regard to pain, four with regard to function, three 
with regard to footwear, and two regarding general foot 
health). Indeed, pain and function assessments are based on 
physical phenomena. Footwear evaluation utilized practical 
aspects related to availability and shoe comfort, and the 
perception of general foot health was based on patients’ self-
assessment of the state of their feet. Several answers were 
permitted for each question permitted, and a Likert-type 
ordinal scale (words or phrases corresponding to a numeric 
scale) was applied to score the answers. The descriptors for 
this scale varied for each domain, and only one response 
was selected to be the most adequate and appropriate. The 
participant then circled this option on the Likert scale. The 
questionnaire did not provide a global score but rather gen-
erated an index for each domain. In order to obtain these 
scores, the responses were fed into a computer program that 
processes the data (The FHSQ, Version 1.03). After process-
ing the data, a score ranging from 0 to 100 was possible. A 
score of 0 represented the worst state of foot health, while a 
score of 100 score was considered the best possible health 
status. Furthermore, the software provided graphical images 
to represent the outcomes. Section 2 evaluated questions that 
reflect four general health-related domains such as general 
health, physical activity, social capacity, and vigor. Questions 
were largely adapted from the Medical Outcomes Study 
36-Item Short-Form Health,15 which has been demonstrated 
to be a valid measurement tool.17 The third section contained 
sociodemographic data such as participants’ age, their medi-
cal characteristics, educational level, profession, civil status, 
and medical records. Furthermore, the Spanish FHSQ version 
showed adequate psychometric properties.18
Finally, the Spanish EuroQol Health Questionnaire 5 
Dimensions, which is a widely used non-disease-specific 
questionnaire to evaluate health-related QoL, negatively cor-
related with the FHSQ for pain (r= –0.445) and positively 
correlated with general foot health and function (r=0.261, 
–0.579), confirming criterion-related validity.18
Ethical considerations
The Bioethics and Biosafety Committee at the University of 
Extremadura approved this study (Spain, registry number: 
28/2017). All participants provided written informed consent 
before inclusion in the study. The ethical standards for human 
experimentation given in the Declaration of Helsinki (World 
Medical Association) and the Council of Europe Convention 
on Human Rights and Biomedicine in addition the Universal 
Declaration of the UNESCO about the Human Genome and 
Human Rights and other appropriate national or institutional 
organizations’ ethical requirements were followed.
Statistical analysis
All variables were examined for normality of distribution 
using the Kolmogorov–Smirnov test, and data were consid-
ered to have a normal distribution if P>0.01. Demographic 
characteristics (such as age, height, weight, and BMI) and 
FHSQ domains (foot pain, foot function, footwear, general 
foot health, general health, physical activity, social capacity, 
and vigor) were described. Mean ± SD for parametric data, 
median ± interquartile range for nonparametric data, and 
maximum and minimum (range) values were used for the 
total sample: women with breast cancer who were under-
going chemotherapy (case group) and the healthy women 
(control group).
Independent Student’s t-tests were performed to deter-
mine if differences were statistically significant when 
showing a normal distribution. Measurements that were not 
normally distributed were tested using the nonparametric 
Mann– Whitney U-test.
FHSQ Version 1.03 was used to obtain foot-related QoL 
scores. In all of the analyses, statistical significance was 
established with a P-value <0.01 and a confidence interval 
of 99%. All analyses were performed with a commercially 
available software (SPSS 19.0, Chicago, IL, USA).
Results
A total sample of 200 women aged between 33 and 80 years 
old, mean ± SD of 51.0±8.75 years, completed the study. 
This sample was divided into 100 women with breast cancer 
who were undergoing chemotherapy (for the case group) and 
100 women without this pathology (healthy women for the 
control group). The sociodemographic characteristics of the 
participants is given in Table 1, and the characteristics did not 
show any statistically significant differences for age, weight, 
height, or BMI (P<0.01).
The results of the comparison between FHSQ scores 
from both groups are shown in Table 2. In section 1 of the 
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FHSQ, four specific domains regarding the foot, ie, pain, 
function, health, and footwear, were evaluated. FHSQ scores 
were higher for foot pain, foot function, and general foot 
health for healthy women compared to women with breast 
cancer. Section 2 assessed four domains of general well-being 
(overall health, physical function, social capacity, and vigor). 
Specifically, FHSQ scores were lower in all domains (general 
health, physical activity, social capacity, and vigor) for women 
undergoing chemotherapy compared to healthy women.
The women with breast cancer undergoing chemotherapy 
treatment showed a lower foot health-related QoL. Statisti-
cally significant differences between cancer and control 
groups were shown for foot pain (P=0.003), foot function 
(P<0001), physical activity (P<0.001), social capacity 
(P<0.001), and vigor (P=0.001). The rest of the domains did 
not show any statistically significant differences between the 
two groups (P≥0.01).
Considering the case group, this study also revealed that 
94% (n=100) of the participants reported having foot problems 
since they had started chemotherapy. Consequently, a physical 
examination revealed that the most frequent alterations in the 
feet were nail abnormalities (46%, including nail plate color 
change, onychogryphosis, onychocryptosis, or onychomyco-
sis), generalized pain (36%), cracks and dryness (20%), par-
esthesia (19%), inflammation (10%), varices (8%), deformed 
fingers (7%), and helomas and hardness (4%). These patholo-
gies were the most frequent, and some patients suffered from 
more than one of these conditions at the same time. Although 
less frequent in the feet, other pathologies observed after 
chemotherapy included cramps, loss of sensation, blistering, 
change in skin coloration, and/or loss of hair and papillomas 
(only in isolated cases). Furthermore, 4% of patients did not 
present any of these signs and symptoms after chemotherapy, 
and thus did not undergo any preventive measures.
Table 1 Comparison of sociodemographic characteristics of the total sample (women with breast cancer undergoing chemotherapy 
and healthy women)
Characteristic Total group
N=200
Breast cancer
N=100
Healthy
N=100
P-value
Age (years) 51.00±8.75a (33–80) 53.60±9.16b (33–80) 51.00±8.75a (45–55) 0.013c
Weight (kg) 68.00±13.00a (40–120) 68.82±12.26b (40–105) 69.00±13.00a (43–120) 0.704c
Height (m) 1.62±0.06b (1.46–1.79) 1.62±0.06b (1.46–1.75) 1.62±0.06b (1.50–1.79) 0.551d
BMI (kg/m2) 26.36±4.72b (17.78–43.51) 26.03±4.39b (17.77–39.04) 26.70±5.03b (18.75–43.51) 0.318d
Notes: In all the analyses, P<0.01 (with a 99% confidence interval) was considered statistically significant. aMedian ± IR (range) was used. bMean ± SD (range) was applied. 
cMann–Whitney U-test was utilized. dStudent’s t-test for independent samples was performed.
Abbreviations: BMI, body mass index; IR, interquartile range; SD, standard deviation.
Table 2 Comparison of FHSQ scores of the total sample (women with breast cancer undergoing chemotherapy and healthy women)
FHSQ domains Total group
N=200
Breast cancer
N=100
Healthy
N=100
P-value
Foot pain 66.56±39.88a
(0–100)
58.77±27.28b
(0–100)
78.00±34.00a
(0–100)
0.003c
Foot function 75.00±44.00a
(0–100)
60.25±28.79b
(0–100)
88.00±31.00a
(0–100)
<0.001c
Footwear 37.50±47.58a
(0–100)
37.50±47.92a
(0–100)
37.50±41.00a
(0–100)
0.659c
General foot health 42.75±35.00a
(0–100)
25.00±35.00a
(0–100)
43.00±35.00a
(0–93)
0.215c
General health 50.00±30.00a
(0–100)
50.00±40.00a
(0–100)
55.00±30.00a
(0–100)
0.195c
Physical activity 61.11±44.25a
(0–100)
50.00±38.89a
(0–100)
78.00±38.00a
(17–100)
<0.001c
Social capacity 62.50±37.50a
(0–100)
50.00±46.88a
(0–100)
75.00±38.00a
(0–100)
<0.001c
Vigor 38.00±31.25a
(0–100)
35.62±31.25b
(0–100)
46.43±24.41b
(0–100)
0.001d
Notes: In all the analyses, P<0.01 (with a 99% confidence interval) was considered statistically significant (bold data). aMedian ± IR (range) was used. bMean ± SD (range) was 
applied. cMann–Whitney U-test was utilized. dStudent’s t-test for independent samples was performed.
Abbreviations: FHSQ, Foot Health Status Questionnaire; IR, interquartile range; SD, standard deviation.
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Discussion
Our aim in this study was to compare the impact on the foot 
health-related QoL between a group of women with breast 
cancer and a group of healthy women who present with nor-
malized reference values. Foot health may be essential for the 
well-being and QoL of women with breast cancer. In a prior 
study on women’s QoL and breast cancer in Arab countries, 
the decrease in physical function in addition to psychological 
and social problems was demonstrated as affecting the QoL of 
women with breast cancer. Nevertheless, foot health-related 
QoL was not evaluated.2 In Iran, a sample of 119 women with 
a mean age of 48.27±11.42 years showed that chemotherapy 
had a negative impact on QoL and social relationship abili-
ties, which was also a significant finding in our study.19 In 
2007, Mitchell demonstrated that chemotherapy imposed 
drastic changes in social and emotional well-being, which 
supported our results that demonstrated significant changes 
in physical activity and social ability domains.20 For Ganz 
et al,21 chemotherapy was considered a concern as it may 
have a long-term impact on QoL. Moreover, Farrel et al22 
highlighted the inability of women undergoing chemotherapy 
to perform tasks and reported that they practiced little or no 
physical activity. All of these contributions reinforced our 
study results.
The physical side effects of chemotherapy are well known, 
as is shown by chemotherapy’s impact on symptoms of the 
hand–foot syndrome.23,24 Patients with hand–foot syndrome 
usually present a spectrum of symptoms ranging from burn-
ing, tingling, and cutaneous erythema to pain, edema, and 
ulcerations in the extremities. Injuries may interfere con-
siderably with even the simplest of daily activities such as 
walking. Thus, the impact on foot health and QoL supported 
our study results and may help to facilitate preventive actions 
or treatments for these symptoms.23
Furthermore, another study reported new data about 
the incidence of all grades of hand–foot syndrome. In this 
study, 27.1% of all patients in whom the breast cancer had 
metastasized presented with this syndrome. In contrast to 
our study, the authors of this study strongly affirmed that 
hand–foot syndrome did not lead to a reduction in QoL and 
justified it by affirming that there was no available validated 
questionnaire for hand–foot syndrome. Moreover, these 
authors highlighted that the treatment stage may influence 
the health status of women with breast cancer.25 In addition, 
these same authors described the finding that only 11.9% of 
patients discontinued their therapies due to adverse events, 
which may have been secondary to metastatic breast cancer 
and no other type of cancer. Compared with other side effects, 
physicians may attach greater importance to dermatological 
or podiatric signs and symptoms in the feet than patients 
actually do.
Our study agrees with a study performed in 2015 in 
which recognition of the first signs and symptoms of hand–
foot syndrome was found accelerate the use of management 
strategies.26 In addition, hand–foot syndrome lesions show 
a range of signs and symptoms from numbness to painful 
erosions. Therefore, this may have a significant impact on 
the QoL in affected patients. In agreement with our study, 
prior studies have tried to find ways to alleviate and prevent 
this syndrome. Thus, prior studies about preventive strategies 
have described the use of topically applied ointments with 
high content of radical protection factor or topical applica-
tions of antioxidants with high protection factors. Both of 
these have been demonstrated to be effective prevention 
strategies in these patients.12
The results of our study suggest that women with breast 
cancer undergoing chemotherapy present significantly dif-
ferent scores on the dimensions related to foot pain, foot 
function, physical activity, social ability, and vigor compared 
to healthy women. Therefore, it seems important to note 
that podiatric and medical care may be useful in women 
with breast cancer who have undergone or are undergoing 
chemotherapy in order to improve their QoL. Comparison 
of the impact of these results with other breast cancer and 
chemotherapy studies may be difficult due to differences in 
criteria and methodological variations. We have not been able 
to find many studies in the literature that used the FHSQ to 
relate QoL and foot health in this group of patients.
This study had important limitations that should be 
acknowledged. A larger and more diverse sample with indi-
viduals from various countries should be recruited in order to 
strengthen the results from the present study regarding che-
motherapy and QoL. Also, additional evaluations of women 
with breast cancer again at 18 and 24 months after initiation of 
treatment would be helpful in order to consider the longer term 
effects of chemotherapy on general and foot health. Finally, 
women with breast cancer undergoing chemotherapy treatment 
were recruited, although data regarding the type of drugs or 
chemotherapy regimens were not collected. These important 
considerations should be addressed in future research studies 
in order to evaluate the relationship between foot symptoms 
and certain chemotherapy drugs. Furthermore, women with 
breast cancer undergoing no chemotherapy treatment (positive 
controls) were not recruited. Future studies should compare the 
foot-related QoL between breast cancer patients undergoing 
and not undergoing chemotherapy treatment.
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Conclusion
In conclusion, measurable differences of association between 
women with breast cancer undergoing chemotherapy and 
those without breast cancer showed an impaired foot health-
related QoL in breast cancer patients undergoing chemother-
apy. Thus, this study provided evidence that chemotherapy 
and breast cancer may be associated with lower scores for 
dimensions related to foot pain, foot function, physical activ-
ity, social ability, and vigor. These items are indicative of a 
deterioration of specific foot-related QoL. Therefore, proper 
foot care and prevention may be extremely important to pre-
vent the onset or development of lesions, pain, infections, 
and/or deformities throughout the chemotherapy process. 
Based on our research, a more exhaustive interventional study 
may be necessary to prevent or mitigate the negative effects 
after chemotherapy in this type of cancer, thereby improving 
foot and general QoL in these patients.
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